ImmunomeNASDAQ: IMNM

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Clay Siegall, PhD, President and CEO of Immunome, will participate in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference on Wednesday, September 4, 2024 at 5:35 P.M. Eastern Time. Interested parties can access the live audio webcast for this conference from the Investor Relations.

Immunome, Inc. (IMNM) came out with a quarterly loss of $0.49 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to loss of $0.46 per share a year ago.

Top-line data from Part B of phase 3 RINGSIDE study, using AL102 for the treatment of patients with desmoid tumors, expected 2nd half of 2025. The global desmoid tumor market is projected to grow to $5.49 billion by 2032. IM-1021 is an antibody-drug conjugate being developed to target ROR1 expressing solid tumors; IND filing to begin a phase 1 study for this program, expected Q1 of 2025.

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company specializing in innovative targeted cancer treatments, has promoted Max Rosett to Chief Financial Officer, starting May 9. Mr. Rosett, who previously served as Executive Vice President of Operations and Interim CFO since January 2024, played a key role in Immunome's swift evolution.

Immunome, Inc. (IMNM) reported a quarterly loss of $0.34 per share, which beat the Zacks Consensus Estimate of a loss of $0.80. This is an improvement from the loss of $0.35 per share reported a year ago.

Immunome (IMNM) lacks the necessary combination of key elements for a potential earnings surprise in its upcoming report. Be ready for the important projections.

IMNM, SLOIF and TMQ have been added to the Zacks Rank #5 (Strong Sell) List on April 4, 2023.

IMNM has acquired an anti-ROR1 antibody-drug conjugate, and ADC platform technology, from Zentalis Pharmaceuticals. IMNM has also acquired AL102 and AL101 from Ayala Pharmaceuticals. AL102 is already in a phase 3 study, with results expected in Q1'25. IMNM is also looking to acquire some antibody-related assets and materials from Atreca, subject to a stockholder vote.

Immunome (IMNM) inks an asset purchase agreement with Ayala Pharmaceuticals to acquire the latter's investigational candidate, AL102, being developed for treating desmoid tumors. Stock rises.